Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Deborah Collyar: What's In It for Patients?

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

David A. Hyman, MD, JD, on Inclusive Shared Savings

May

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Deborah Collyar: What's In It for Patients?

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

David A. Hyman, MD, JD, on Inclusive Shared Savings

AI Avatar Doctor Leads to Improved Patient Understanding of Radiation Treatment Plans

Novel Gene Fusion Detector for Pediatric B-ALL Shows High Sensitivity

ASCENDE-RT 15-Year Update Shows No Overall Survival Benefit, With ‘Borderline’ Signal for Fewer Deaths

Study Shows Potential Missing Patient Information in SEER Database

Recurrence With Concurrent or Sequential Radiation Dose Escalation to the Surgical Cavity in High-Risk Early Breast Cancer